Literature DB >> 19833566

Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year.

Jose L Cabriada1, Nora Ibargoyen, Anaiansi Hernández, Antonio Bernal, Agustín Castiella.   

Abstract

BACKGROUND: Leukocytapheresis (LAP) could be an alternative treatment for steroid-dependent ulcerative colitis (UC). AIMS: To assess the duration of response at 1 year after this treatment. PATIENTS AND METHODS: A prospective study in 18 patients with steroid-dependent UC treated with LAP plus steroids after failure or intolerance to immunomodulators. Clinical and endoscopic (Mayo Clinic index) examinations were performed at 1 month after the last apheresis and at 12 months. The clinical, endoscopic remission and the relapse during the 1-year follow-up were evaluated based on standard parameters.
RESULTS: Induction of remission: clinical remission: 10/18 (55%). Partial response: 4. Endoscopic remission: 9 (50%), always accompanied by clinical remission. A significant correlation was observed between clinical remission and endoscopic remission (r(s)=0.894; p< or =0.001). At 1 year: sustained steroid-free clinical remission in 9 (50%), all of whom presented initial endoscopic remission. Remission and relapse before 1 year in 17%. A tendency for sustained remission at 1 year was observed when initial endoscopic remission was achieved.
CONCLUSIONS: Initial remission can be maintained at 1 year in half of the patients without the need for additional steroids. Complete remission and endoscopic mucosal healing is proposed as an objective for achieving a lasting response. Copyright 2009 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19833566     DOI: 10.1016/j.dld.2009.09.001

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  7 in total

1.  Leukocytapheresis for steroid-dependent ulcerative colitis in clinical practice: results of a nationwide Spanish registry.

Authors:  J L Cabriada; E Domènech; N Ibargoyen; V Hernández; J Clofent; D Ginard; I Gutiérrez-Ibarluzea; J Hinojosa
Journal:  J Gastroenterol       Date:  2011-11-23       Impact factor: 7.527

Review 2.  Steroid-sparing strategies in the management of ulcerative colitis: efficacy of leukocytapheresis.

Authors:  Manabu Shiraki; Takayuki Yamamoto
Journal:  World J Gastroenterol       Date:  2012-11-07       Impact factor: 5.742

3.  Long-interval Cytapheresis as a Novel Therapeutic Strategy Leading to Dosage Reduction and Discontinuation of Steroids in Steroid-dependent Ulcerative Colitis.

Authors:  Masahiro Iizuka; Takeshi Etou; Makoto Kumagai; Atsushi Matsuoka; Yuka Numata; Shiho Sagara
Journal:  Intern Med       Date:  2017-09-15       Impact factor: 1.271

4.  Cytapheresis re-induces high-rate steroid-free remission in patients with steroid-dependent and steroid-refractory ulcerative colitis.

Authors:  Masahiro Iizuka; Takeshi Etou; Yosuke Shimodaira; Takashi Hatakeyama; Shiho Sagara
Journal:  World J Gastroenterol       Date:  2021-03-28       Impact factor: 5.742

Review 5.  A review on the current status and definitions of activity indices in inflammatory bowel disease: how to use indices for precise evaluation.

Authors:  Masahiro Kishi; Fumihito Hirai; Noritaka Takatsu; Takashi Hisabe; Yasumichi Takada; Tsuyoshi Beppu; Ken Takeuchi; Makoto Naganuma; Kazuo Ohtsuka; Kenji Watanabe; Takayuki Matsumoto; Motohiro Esaki; Kazutaka Koganei; Akira Sugita; Keisuke Hata; Kitarou Futami; Yoichi Ajioka; Hiroshi Tanabe; Akinori Iwashita; Hirotaka Shimizu; Katsuhiro Arai; Yasuo Suzuki; Tadakazu Hisamatsu
Journal:  J Gastroenterol       Date:  2022-03-02       Impact factor: 7.527

Review 6.  Efficacy of cytapheresis in patients with ulcerative colitis showing insufficient or lost response to biologic therapy.

Authors:  Masahiro Iizuka; Takeshi Etou; Shiho Sagara
Journal:  World J Gastroenterol       Date:  2022-09-14       Impact factor: 5.374

7.  Therapeutic landscape for ulcerative colitis: where is the Adacolumn(®) system and where should it be?

Authors:  Maurizio Vecchi; Piero Vernia; Gabriele Riegler; Renata D'Incà; Vito Annese; Siro Bagnoli
Journal:  Clin Exp Gastroenterol       Date:  2013-01-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.